Post by sportsrancho on Jun 25, 2016 12:55:53 GMT -5
Diabetes Innovation Challenge
Challenge Summary
In diabetes, transformative innovation remains elusive. Despite breathtaking advances in basic science, the rate at which new clinical therapies are introduced has declined. And while there have been advances in devices and technologies, tremendous opportunity remains for disruptive approaches that improve diabetes management and ease the burden of care.
T1D Exchange and M2D2, a joint venture of the University of Massachusetts Lowell and Worcester campuses that incubates medical device start-ups, have announced the first annual Diabetes Innovation Challenge (2016).
The collaborative objective of T1D Exchange and M2D2 is for the open competition to identify and accelerate transformational advancements in diabetes research and care.
The Diabetes Innovation Challenge will provide up to two awards of up to $150,000 in cash or in-kind services provided by T1D Exchange, M2D2, and Challenge sponsors, including JDRF, the leading global organization funding type 1 diabetes research program sponsors.
Interested in becoming a Challenge Sponsor?
We invite industry, advocacy, and other organizations interested in new and disruptive approaches to become a Challenge sponsor. A sponsorship opportunity will align your organization with the goal of advancing diabetes treatment—while helping us reach a global market of innovators.
Learn more
Who should apply to the Diabetes Innovation Challenge?
it is open to both type 1 and type 2 diabetes opportunities as products developed for one disease may have cross-utility for the other. The Diabetes Innovation Challenge is open to all academic and for-profit inventors, innovators and companies developing or seeking to develop medical device, diagnostics, therapeutics, digital health technologies and clinical care improvements in diabetes.
T1D Exchange and M2D2 are seeking projects and proposals in the following categories:
Devices – such as novel glucose sensing, insulin delivery, cellular therapy delivery technologies
Diagnostics – such as novel low costs tests for research and screening: early diagnosis – prevention; autoantibodies, C-Peptide or other markers such as beta cell death and risk of diabetic complications
Therapeutics – such as smart insulins, glucagons, immune modulating, beta-cell regeneration
Technologies – such as new and disruptive approaches to personal management or care of type 1 diabetes; broad range of applications; patient or clinician
The program will consist of two tracks:
early stage projects (up to and including pre-clinical)
and translation projects (Clinical Phase I-III).
Qualified Applicants receive visibility and may win cash and in-kind awards
Qualified applicants will be chosen to present in front of investor, legal, industry, foundation and academic partners.
Pre-clinical and Translational opportunities will be presented at UMass Worcester on September 29th
Early stage opportunities will be presented at UMass Lowell on Oct 5th
The two events will be co-promoted by T1D Exchange and M2D2 to investor, industry, foundation and academic partners to provide all applicants an audience to showcase innovative ideas.
From the two initial events, a pool of finalists will be chosen to present at a special T1D Exchange showcase event on October 20th at the Royal Sonesta, Boston in front of an esteemed panel of judges and others.
Two awardees will be announced during the T1D Exchange Annual Meeting on Friday October 21st. This meeting convenes select professionals from the investment, industry, academic and foundation communities.
